Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Similar articles for PubMed (Select 23950206)

1.

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J.

Cancer Discov. 2013 Nov;3(11):1238-44. doi: 10.1158/2159-8290.CD-13-0132. Epub 2013 Aug 15.

2.

Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.

Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, Keilholz U.

Cancer Biol Ther. 2010 Nov 1;10(9):860-4. doi: 10.4161/cbt.10.9.13323. Epub 2010 Nov 1.

3.

EGFR-mutated lung cancer in Li-Fraumeni syndrome.

Michalarea V, Calcasola M, Cane P, Tobal K, Izatt L, Spicer J.

Lung Cancer. 2014 Sep;85(3):485-7. doi: 10.1016/j.lungcan.2014.06.017. Epub 2014 Jun 30.

PMID:
25047674
4.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Review.

PMID:
18594499
5.

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J.

Clin Cancer Res. 2010 May 1;16(9):2688-95. doi: 10.1158/1078-0432.CCR-09-3407. Epub 2010 Apr 20.

6.

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.

Ross HJ, Blumenschein GR Jr, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA.

Clin Cancer Res. 2010 Mar 15;16(6):1938-49. doi: 10.1158/1078-0432.CCR-08-3328. Epub 2010 Mar 9.

7.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.

8.

Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.

Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, Netto CB, Cossio SL, Roth DE, Brunetto AL, Zagonel-Oliveira M, Martel-Planche G, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P.

Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.

9.

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.

BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188.

10.

Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, Lyerly HK, Clay TM.

Int J Cancer. 2010 Jun 15;126(12):2893-903. doi: 10.1002/ijc.24995.

11.
12.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.

Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M.

Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9.

PMID:
23472669
13.

A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.

Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, Jones JL, Eccles DM.

J Med Genet. 2010 Nov;47(11):771-4. doi: 10.1136/jmg.2010.078113. Epub 2010 Aug 30. Erratum in: J Med Genet. 2011 Mar;48(3):216.

PMID:
20805372
14.

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Johnston SR, Leary A.

Drugs Today (Barc). 2006 Jul;42(7):441-53. Review.

PMID:
16894399
15.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL.

Cancer Cell. 2006 Jul;10(1):25-38.

16.

Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.

Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y.

Mol Cell Proteomics. 2012 Dec;11(12):1741-57. doi: 10.1074/mcp.M112.019919. Epub 2012 Sep 10.

17.

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M.

Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Review.

PMID:
20100635
18.

Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC.

Cancer Res. 2010 Jun 15;70(12):4795-800. doi: 10.1158/0008-5472.CAN-09-0851. Epub 2010 May 25.

19.

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.

Oncogene. 2011 Sep 29;30(39):4097-106. doi: 10.1038/onc.2011.111. Epub 2011 Apr 18.

PMID:
21499301
20.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk